HonorStocks Biotech Gold Oil Mining China Asian MENU
Biotech Gold Oil Mining China Asian
Find Tomorrow's Winners Today

Stock technical analysis
Rating Flag Rating Flag Rating Flag Rating Flag Rating Flag
sell neutral buy
Clovis Oncology, Inc. (CLVS)
5.84  0.06  (1.04%) 06-14 22:52
Open: 5.9 High: 6.245
Pre.close: 5.78 Low: 5.8
Volume: 9,669,686 Ave vol: 11,325,334
52w High: 11.1 52w Low: 4.08
MA(50): 5.596 MA(200): 6.068
EPS: -3.636 P/E Ratio: 0
Company profile
Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Website: http://www.clovisoncology.com
Market Cap (M): 611
Shares Out (M): 105
Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, the European Union, and internationally. The company offers Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase for recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer. It also provides lucitanib, an oral inhibitor of the tyrosine kinase activity of vascular endothelial growth factor receptors, platelet-derived growth factor receptors alpha and beta, and fibroblast growth factor receptors. The company distributes its products primarily through specialty distributors and pharmacy providers to patients and health care providers. Clovis Oncology, Inc. has license agreements with Pfizer Inc., AstraZeneca UK Limited, and Advenchen Laboratories LLC; collaboration agreements with Bristol-Myers Squibb Company and Myriad Genetics, Inc.; and a partnership with Foundation Medicine, Inc. The company was founded in 2009 and is headquartered in Boulder, Colorado.
Technical analysis
Overall: Neutral
MA: Bearish MACD: Bullish
KDJ: Bearish RSI: Bullish
Target 1: 7.45 Target 2: 8.46
Resist 1: 6.38 Resist 2: 7.24
Support 1: 4.99 Support 2: 4.15
Company key metrics
Revenue per Share: 1.8642
Net Income per Share: -4.1835
Cash per Share: 2.722
Book Value per Share: -1.7987
Price to Sales: 4.2378
Price to Book Value: -4.392
Earnings Yield: -0.5296
Dividend Yield: 0
Debt to Equity: -3.4379
Debt to Assets: 1.2622
Financial analysis
Price to Book Value: Underperform
Return on Assets: Underperform
Return on Equity: Outperform
Discounted cash flow: Outperform
Price to Earnings: Underperform
Debt to Equity: Underperform
Stock Charts

HonorStocks, Find Tomorrow's Winners Today

©HonorStocks.com | U.S. stock markets, stock quotes and stock analysis. Data and information is provided for informational purposes only, is not intended for trading purposes and is not investment advice. Neither HonorStocks.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. Market data provided by: IEX and Financial Modeling Prep

Privacy Policy: Third parties, including Google, may be placing and reading cookies on your browsers, or other methods to collect information as a result of ad serving on this website. Google's use of advertising cookies enables it and its partners to serve ads to you based on your visit to this site and/or other sites on the Internet. You may opt out of personalized advertising by visiting Ads Settings. If you choose to use this website, you agree to the collection and use of information in relation to this policy. The information collected is used for providing and improving the ads Service. We will not use or share information with anyone, and we do not store any data from users.